Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models. [PDF]
Santiago-O'Farrill JM +17 more
europepmc +1 more source
Model for Predicting Serious Hematological Adverse Events in Individuals With Ovarian Cancer Receiving Poly (Adenosine Diphosphate Ribose) Polymerase Inhibitor Treatment: Prospective Cohort Study. [PDF]
Lian X, Lei Y.
europepmc +1 more source
Poly(Adenosine Diphosphate Ribose) Polymerase (PARP) Inhibitors in the Treatment of Advanced Ovarian Cancer: A Narrative Review. [PDF]
Dewani D, Jaiswal A, Karwade P.
europepmc +1 more source
Role of Poly Adenosine Diphosphate Ribose Polymerase Inhibitors in Advanced Stage Ovarian Cancer. [PDF]
Arora E +5 more
europepmc +1 more source
Kinetic Analysis and Metabolism of Poly(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted <sup>18</sup>F-Fluorthanatrace PET in Breast Cancer. [PDF]
Young AJ +19 more
europepmc +1 more source
Studies on Poly Adenosine Diphosphate-Ribose
Teruo Shima +4 more
openaire +1 more source
Poly(adenosine diphosphate ribose) polymerase inhibition in isocitrate dehydrogenase 1 and 2-mutant tumors: Bridging science with the clinic. [PDF]
Nassif Haddad E, Javle MM, Yap TA.
europepmc +1 more source
Kinetic and mutational studies of the adenosine diphosphate ribose hydrolase from Mycobacterium tuberculosis. [PDF]
O'Handley SF +6 more
europepmc +1 more source
Poly(adenosine diphosphate-ribose) polymerase as therapeutic target: lessons learned from its inhibitors. [PDF]
Cseh AM +3 more
europepmc +1 more source

